{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:56:49Z","timestamp":1792785409719,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Dixon Foundation and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health Training","award":["5T32AI052069"],"award-info":[{"award-number":["5T32AI052069"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["K08AI108691"],"award-info":[{"award-number":["K08AI108691"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clinthera.2018.07.006","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T18:55:54Z","timestamp":1533927354000},"page":"1282-1298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Antiviral Therapies for Herpesviruses: Current Agents and New Directions"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3516","authenticated-orcid":false,"given":"Claudette L.","family":"Poole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.07.006_bib0001","first-page":"1802","article-title":"Herpesviridae. In Fields Virology","author":"Pellett","year":"2013"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0002","series-title":"Clinical Virology","first-page":"415","article-title":"Herpes Simplex Viruses","author":"Whitley","year":"2017"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0003","series-title":"Clinical Virology","first-page":"459","article-title":"Varicella Zoster Virus","author":"Gershon","year":"2017"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0004","series-title":"Clinical Virology","first-page":"481","article-title":"Cytomegalovirus","author":"Griffiths","year":"2017"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.antiviral.2013.09.012","article-title":"Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey","volume":"100","author":"Burrel","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0007","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0008","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0009","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.idc.2010.07.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coviro.2014.06.003","article-title":"Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance","volume":"8","author":"James","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coviro.2014.09.019","article-title":"The development of new therapies for human herpesvirus 6","volume":"9","author":"Prichard","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0012","series-title":"Clinical Virology","first-page":"523","article-title":"Epstein-Barr Virus","year":"2017"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0013","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/00007890-199709270-00010","article-title":"Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy","volume":"64","author":"Darenkov","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0014","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","article-title":"Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients","volume":"21","author":"Malouf","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0015","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","article-title":"Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients","volume":"5","author":"Funch","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0016","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/lt.21498","article-title":"Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus","volume":"14","author":"Hierro","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0017","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0018","series-title":"Clinical Virology","first-page":"549","article-title":"Kaposi's sarcoma associated herpes virus (HHV8)","author":"Chang","year":"2017"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1542\/peds.2013-4251","article-title":"Impact of vaccination on the epidemiology of varicella: 1995-2009","volume":"134","author":"Baxter","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0022","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"6","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0023","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0134","article-title":"Incidence of neonatal herpes simplex virus infections in the United States, 2006","volume":"127","author":"Flagg","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0024","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/01.olq.0000258432.33412.e2","article-title":"Incidence of neonatal herpes simplex virus infections in a managed-care population","volume":"34","author":"Whitley","year":"2007","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","article-title":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters","volume":"31","author":"Chan","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0026","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/590668","article-title":"Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis","volume":"198","author":"Duan","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2018.07.006_bib0028","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/422364","article-title":"Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients","volume":"39","author":"Levin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0029","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/tri.13142","article-title":"Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant\u2014a retrospective study","volume":"6","author":"Ariza-Heredia","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0031","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/tid.12311","article-title":"The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations","volume":"16","author":"Choi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0032","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/rmv.1787","article-title":"Antiviral drug resistance in herpesviruses other than cytomegalovirus","volume":"24","author":"Piret","year":"2014","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0033","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/tid.12317","article-title":"Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients","volume":"16","author":"Gagermeier","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013011","article-title":"Herpes simplex viruses: mechanism of DNA replication","volume":"4","author":"Weller","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","article-title":"Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0036","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","article-title":"Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections","volume":"39","author":"Faulds","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0037","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0038","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0039","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0040","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0041","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2741\/1964","article-title":"The two helicases of herpes simplex virus type 1 (HSV-1)","volume":"11","author":"Chattopadhyay","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm0402-327","article-title":"New anti-HSV therapeutics target the helicase-primase complex.[comment]","volume":"8","author":"Crumpacker","year":"2002","journal-title":"Nature Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0043","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0044","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0045","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1016\/S0021-9258(18)83248-3","article-title":"Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate","volume":"264","author":"Reardon","year":"1989","journal-title":"J Biologic Chemistry"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0046","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/342968","article-title":"An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children","volume":"186","author":"Nadal","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0047","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1074\/jbc.M709530200","article-title":"Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase","volume":"283","author":"Lai","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0048","first-page":"116","article-title":"Monitoring the safety of antivirals. The example of the acyclovir experience","volume":"85","author":"Tilson","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0049","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jpeds.2015.01.023","article-title":"Intravenous acyclovir and renal dysfunction in children: a matched case control study","volume":"166","author":"Rao","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0050","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jpeds.2015.03.053","article-title":"Acyclovir dosing and acute kidney injury: deviations and direction","volume":"166","author":"Steinberg","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0051","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1542\/peds.108.2.230","article-title":"Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections","volume":"108","author":"Kimberlin","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0052","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM198601163140303","article-title":"Vidarabine versus acyclovir therapy in herpes simplex encephalitis","volume":"314","author":"Whitley","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0053","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/infdis\/165.3.450","article-title":"Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group","volume":"165","author":"Whitley","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0054","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJM199102143240703","article-title":"A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group","volume":"324","author":"Whitley","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral acyclovir suppression and neurodevelopment after neonatal herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0056","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.pcl.2005.02.006","article-title":"Antiviral therapies in children: has their time arrived","volume":"52","author":"Kimberlin","year":"2005","journal-title":"Pediatr Clinics North Am"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0057","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2011.12.053","article-title":"Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series","volume":"161","author":"Pinninti","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0058","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/bdra.20013","article-title":"Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999","volume":"70","author":"Stone","year":"2004","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0059","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/649212","article-title":"Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age","volume":"50","author":"Kimberlin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.7.1.1","article-title":"\u201cThe end of innocence\u201d revisited: resistance of herpesviruses to antiviral drugs","volume":"7","author":"Field","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0061","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/infdis\/161.4.711","article-title":"Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS","volume":"161","author":"Gateley","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0062","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJM199312093292405","article-title":"Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient","volume":"329","author":"Kost","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0063","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0031-3955(16)38980-5","article-title":"Resistance to antivirals","volume":"42","author":"Laufer","year":"1995","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0064","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00006454-199603000-00014","article-title":"Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I\/II trial","volume":"15","author":"Kimberlin","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0065","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00705-003-0124-7","article-title":"Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials","volume":"148","author":"Sarisky","year":"2003","journal-title":"Arch Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0066","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/adc.70.2.133","article-title":"Acyclovir resistant varicella zoster and HIV infection","volume":"70","author":"Lyall","year":"1994","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0067","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/358160a0","article-title":"Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir","volume":"358","author":"Littler","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0068","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/AAC.23.5.676","article-title":"Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine","volume":"23","author":"Smee","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0069","unstructured":"Roche Pharmaceuticals. Valganciclovir package insert."},{"key":"10.1016\/j.clinthera.2018.07.006_bib0070","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","article-title":"Ganciclovir. An update of its therapeutic use in cytomegalovirus infection","volume":"48","author":"Markham","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0071","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0072","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0073","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","article-title":"Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers","volume":"37","author":"Brown","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0074","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/00912709922008452","article-title":"Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects","volume":"39","author":"Jung","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0075","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","article-title":"Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients","volume":"44","author":"Wiltshire","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0076","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0077","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/JVI.68.7.4427-4431.1994","article-title":"Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir","volume":"68","author":"Lurain","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0078","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1345\/aph.1A393","article-title":"Valganciclovir: an advance in cytomegalovirus therapeutics","volume":"36","author":"Cocohoba","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0079","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/314747","article-title":"Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir","volume":"179","author":"Drew","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/324672","article-title":"Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis","volume":"184","author":"Boivin","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0081","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1086\/382753","article-title":"Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients","volume":"189","author":"Boivin","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0082","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","article-title":"Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections","volume":"48","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0083","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/infdis\/163.6.1348","article-title":"Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS","volume":"163","author":"Jacobson","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0084","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/167.5.1184","article-title":"Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients","volume":"167","author":"Dieterich","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0085","unstructured":"Drugs@FDA: FDA Approved Drug Products\u2014Foscavir. US Food and Drug Administration."},{"key":"10.1016\/j.clinthera.2018.07.006_bib0086","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.37.5.1010","article-title":"Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis","volume":"37","author":"Hengge","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0087","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1989","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0088","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jcem-72-5-1130","article-title":"Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism","volume":"72","author":"Jacobson","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0089","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/infdis\/169.1.193","article-title":"Foscarnet-resistant herpes simplex virus infection in patients with AIDS","volume":"169","author":"Safrin","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0090","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/clinids\/18.4.570","article-title":"Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)","volume":"18","author":"Snoeck","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0091","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0026-895X(25)08828-5","article-title":"Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"41","author":"Ho","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0092","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/AAC.35.8.1596","article-title":"Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice","volume":"35","author":"Yang","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0093","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-126-4-199702150-00002","article-title":"Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial","volume":"126","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0094","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/426594","article-title":"Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient","volume":"40","author":"Fanourgiakis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0096","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/01.inf.0000091399.29505.21","article-title":"Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant","volume":"22","author":"Hatakeyama","year":"2003","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0097","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/00007890-200210150-00027","article-title":"Intravenous cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient","volume":"74","author":"Carter","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0098","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1034\/j.1600-6143.2003.30202.x","article-title":"Treatment of refractory BK virus-associated nephropathy with cidofovir","volume":"3","author":"Kadambi","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0099","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007890-200301150-00020","article-title":"Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults","volume":"75","author":"Vats","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0100","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0101","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0102","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/AAC.39.4.882","article-title":"Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria","volume":"39","author":"Polis","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0103","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/infdis\/170.3.570","article-title":"Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS","volume":"170","author":"Lalezari","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0104","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1128\/JVI.66.12.7146-7152.1992","article-title":"Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents","volume":"66","author":"Lurain","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/AAC.37.1.19","article-title":"A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives","volume":"37","author":"Sullivan","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0106","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0107","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0108","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid In vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0110","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0111","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0112","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0113","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0114","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/AAC.49.2.656-662.2005","article-title":"Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro","volume":"49","author":"Wan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/421912","article-title":"Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection","volume":"190","author":"Bidanset","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0116","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/AAC.48.9.3516-3522.2004","article-title":"Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0117","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/AAC.00545-11","article-title":"CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections","volume":"55","author":"Prichard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Research"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0119","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0121","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0122","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0123","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/jmv.23329","article-title":"Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial","volume":"84","author":"Tyring","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0124","series-title":"The 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"#V-1256a: Activity of valomaciclovir in infectious mononucleosis due to primary Epstein-Barr virus infection","author":"Balfour","year":"2009"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0166-3542(02)00010-4","article-title":"Metabolic pathways of N-methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells","volume":"55","author":"Zalah","year":"2002","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0126","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.50.4.1336-1341.2006","article-title":"Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections","volume":"50","author":"Prichard","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3851\/IMP1901","article-title":"Efficacy of orally administered low dose N-methanocarbathymidine against lethal herpes simplex virus type-2 infections of mice","volume":"22","author":"Quenelle","year":"2011","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.antiviral.2011.08.021","article-title":"N-methanocarbathymidine is more effective than acyclovir for treating neonatal herpes simplex virus infection in guinea pigs","volume":"92","author":"Bernstein","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2013.08.024","article-title":"Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir","volume":"100","author":"Field","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0131","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drup.2010.11.002","article-title":"Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus","volume":"14","author":"Field","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0132","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0133","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkq135","article-title":"Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor","volume":"65","author":"Sukla","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/095632020701800102","article-title":"High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1","volume":"18","author":"Biswas","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0135","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005701","article-title":"CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections","volume":"12","author":"van Diemen","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.clinthera.2018.07.006_bib0137","doi-asserted-by":"crossref","first-page":"e12694","DOI":"10.1111\/cmi.12694","article-title":"CRISPR\/Cas9, a powerful tool to target human herpesviruses","volume":"19","author":"van Diemen","year":"2017","journal-title":"Cell Microbiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T05:00:53Z","timestamp":1751778053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818303114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":137,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0149291818303114"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Therapies for Herpesviruses: Current Agents and New Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}